With no single headline event driving DexCom (DXCM) recently, investors are watching the stock after a gain of about 21% over the past month and roughly 7% over the past 3 months. See our latest ...

BofA raised the firm’s price target on DexCom (DXCM) to $90 from $80 and keeps a Buy rating on the shares post the Q3 report. DexCom did a good job instilling confidence in its 2025 revenue target ...

California-based DexCom, Inc. (DXCM) is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. With a market cap of $22.3 billion, ...

DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...

DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...

Given its strong position in its market, it's natural to wonder why DexCom stock was beaten down -- and whether it can get back up and outperform in the years ahead. In July, shares of DexCom fell by ...

There's been a huge drop-off in DexCom's growth rate of late, and that's a key reason investors believe that there may be a strong correlation between rising GLP-1 use and demand for CGMs. The company ...

DexCom Inc. DXCM stock is trading higher on Monday after the diabetes management company reported positive results from its ...

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...